Print this page
-
A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors.
Protocol: 072310Principal Investigator:
- Matthew Deek (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Rectum
Prostate
Small Intestine -
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative
Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant
Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA)
and Taxane-based Chemotherapy
Protocol: 082306Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Prostate -
A Phase 3, Randomized, Open-label Study of MK-5684 (004) Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)
Protocol: 082307Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Prostate -
Understanding the Role of p53 in the Development and Progression of Oligometastatic Castration-Sensitive Prostate Cancer.
Protocol: 152102Principal Investigator:
- Matthew Deek (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Prostate -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah Toppmeyer M.D. (Rutgers University)
Applicable Disease Sites: Pancreas
Melanoma, Skin
Colon
Ovary
Soft Tissue
Prostate
Kidney
Breast -
Personalized Oncology Promoting Equity for Black Lives (PROPEL)
Protocol: 132309Principal Investigator:
- Anita Kinney PhD,RN (Rutgers University)
Applicable Disease Sites: Corpus Uteri
Prostate
Pancreas
Breast
Ovary
Colon